I make a donation

APTITUDE

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor

Terminée

Colloquium "Endocardite infectieuse" (jeudi 07 novembre 2024)
Réservez vos places !

La Fondation de l'AP-HP attribue le Grand Prix Scientifique 2024 au Pr Gilles Montalescot

Pod'casts Interview d'experts

P&R Agenda
Au programme prochainement...

Parole & Réaction vous invite à découvrir les Pod'P&R, les pod'casts d'infos médicales !

objectif

Monocentric, biological, prospective, ex-vivo, trial aiming at comparing the effects of in vivo platelet transfusion on platelet activation in patients with bleeding caused by aorto-coronary bypass, depending on the type of inhibitor of the P2Y12 receptor (clopidogrel, prasugrel or ticagrelor) and the effects of ex-vivo transfusion with un-treated PRP on the normalisation of the platelet reactivity in SCA/PCI patients after a dosis of clopidogrel, prasugrel ou ticagrelor.

date de réalisation

2014

nombre de patients

nombre de centres participants

Monocentric (Pitié-Salpêtrière)

type de financement

Public (INSERM) and private (ACTION Group)

Référence

n°301111, CNIL n°1547216v0

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor : the APTITUDE study

Publication

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P₂Y₁₂ inhibition by clopidogrel, prasugrel, and ticagrelor : the APTITUDE study
Stephen A O'Connor, Julien Amour, Anne Mercadier, Réjane Martin, Mathieu Kerneis, Jérémie Abtan, Delphine Brugier, Johanne Silvain, Olivier Barthélémy, Pascal Leprince, Gilles Montalescot, Jean-Philippe Collet, ACTION Study Group
Publicated in Circulation : Cardiovascular Interventions

Autres études

ARGO

En cours

Colchicine versus Placebo in Acute myocarditis patients to Reduce Late Gadolinium Enhancement mass on CMR and the risk of Clinical Outcomes

ACORES-2

En cours

Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI